Laboratory of Immunopharmacology and Molecular Biology, São Francisco University Medical School, Bragança Paulista 12916-900, Brazil.
Laboratory of Cell and Molecular Tumor Biology and Bioactive Compounds, São Francisco University Medical School, Bragança Paulista 12916-900, Brazil.
Int J Mol Sci. 2022 Apr 8;23(8):4121. doi: 10.3390/ijms23084121.
Intestinal diseases, such as inflammatory bowel diseases (IBDs) and colorectal cancer (CRC), are a significant source of morbidity and mortality worldwide. Epidemiological data have shown that IBD patients are at an increased risk for the development of CRC. IBD-associated cancer develops against a background of chronic inflammation and oxidative stress, and their products contribute to cancer development and progression. Therefore, the discovery of novel drugs for the treatment of intestinal diseases is urgently needed. Licorice () has been largely used for thousands of years in traditional Chinese medicine. Licorice and its derived compounds possess antiallergic, antibacterial, antiviral, anti-inflammatory, and antitumor effects. These pharmacological properties aid in the treatment of inflammatory diseases. In this review, we discuss the pharmacological potential of bioactive compounds derived from Licorice and addresses their anti-inflammatory and antioxidant properties. We also discuss how the mechanisms of action in these compounds can influence their effectiveness and lead to therapeutic effects on intestinal disorders.
肠道疾病,如炎症性肠病(IBD)和结直肠癌(CRC),是全球发病率和死亡率的重要来源。流行病学数据表明,IBD 患者发生 CRC 的风险增加。IBD 相关癌症是在慢性炎症和氧化应激的背景下发展的,其产物有助于癌症的发生和发展。因此,迫切需要发现治疗肠道疾病的新药。甘草()在中医药中已被广泛使用数千年。甘草及其衍生化合物具有抗过敏、抗菌、抗病毒、抗炎和抗肿瘤作用。这些药理特性有助于治疗炎症性疾病。在这篇综述中,我们讨论了源自甘草的生物活性化合物的药理潜力,并探讨了它们的抗炎和抗氧化特性。我们还讨论了这些化合物的作用机制如何影响它们的有效性,并导致对肠道疾病的治疗效果。